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ABSTRACT 
 
Background:  In recent years, clinical practice guidelines (CPGs) have become more 
heavily relied upon by clinicians to navigate the expansive, ever-changing scientific 
literature.  With no central guideline-issuing body, guidelines are issued by a variety 
of medical organizations and governmental agencies; with no mandatory standards 
for guideline development process, these guidelines are not all of the same quality.  
The contentious prostate cancer screening debate provides a useful backdrop to 
examine the development process and role of clinical practice guidelines. 
Methods: To assess the guideline development processes of the five “major” guideline-
publishing bodies on prostate cancer screening (ACP, ACPM, ACS, AUA, and 
USPSTF), pre-defined variables were used to evaluate important characteristics of 
publishing bodies, CPG development committees, evidence review processes, 
clinical recommendations, and conflicts of interest.  These variables were chosen to 
reflect Institute of Medicine standards as well as to highlight important steps in the 
recommendation development process. 
Findings: All five recommendation statements fell considerably short of IOM standards, 
particularly in regards to committee selection, guideline crafting and addressing 
conflicts of interest. The CPG-issuing groups published a variety of 
recommendations statements ranging from insufficient evidence to recommend 
prostate cancer screening to recommending against screening in all men. 
Conclusion: IOM standards as a whole have yet to gain traction with CPG-issuing 
groups, although some changes have been made since they were issued in 2011.  In 
a medicine culture where CPGs are often treated as standards of care, it is important 
that clinicians carefully and critically review recommendation statements, including 
the process by which they were developed. 
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 1 
Introduction  
 
Clinical practice guidelines (CPGs) have become an increasingly important part of 
medical practice over the past few decades.  Physicians from all specialties rely heavily on 
CPGs to determine courses of action for individual patients, insurance companies and other 
payers use CPGs to help determine reimbursement, and CPGs are often utilized as 
benchmarks in quality improvement programs in physician offices and hospitals (Nissen, 2011).  
In these and many other ways, CPGs play an important role as undergirding for both physician 
and patient decision-making.  In the current climate of medical practice where CPGs are thought 
of as standards rather than guidelines, it is imperative that we critically and deliberately examine 
the overall composition and individual members of the panels that publish these 
recommendations, as well as the CPG development process as a whole.  
The issue of prostate cancer screening provides a useful example of the difficulties inherent 
in crafting a CPG.  PSA-based testing for prostate cancer is a subject with diverse clinical and 
scientific stakeholders which includes urologists and other specialists, primary care providers, 
cancer and prevention societies, public health and policy experts, and most importantly, 
patients.  The issue of screening for prostate cancer also carries an ever-changing evidence 
base, which has been significantly shifted in the past few years by the publication of somewhat 
conflicting, large RCTs, and is fueled by heated debate and controversy between groups like the 
U.S. Preventive Services Task Force and the American Urological Association over the 
appropriate course of action moving forward. 
 
Background and Significance 
 
Often in medicine, clinicians are faced with counseling patients about medical decisions 
for which the evidence base is of poor quality, incomplete, or seemingly conflicting.  In these 
situations, health care providers often turn to clinical practice guidelines (or CPGs) for guidance.  
According to the Institute of Medicine (IOM), 
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 “…clinical practice guidelines are statements that include recommendations 
intended to optimize patient care that are informed by a systematic review of 
evidence and an assessment of the benefits and harms of alternative care 
options. Rather than dictating a one-size-fits-all approach to patient care, clinical 
practice guidelines offer an evaluation of the quality of the relevant scientific 
literature and an assessment of the likely benefits and harms of a particular 
treatment. This information enables healthcare providers to proceed accordingly, 
selecting the best care for a unique patient based on his or her preferences” 
(2011: 1). 
 
In order to help clinicians make sense of the increasingly complex and often conflicting 
mountain of clinical and research data generated daily, the U.S. Preventive Services Task Force 
(USPSTF), medical specialty and subspecialty societies, government agencies, and a myriad of 
other organizations publish CPGs on topics ranging from prevention strategies to diagnostic 
criteria to treatment protocols.  Kuehn counts about 2700 guidelines in the Agency for 
Healthcare Research and Quality (AHRQ) National Guideline Clearinghouse, and more than 
6800 in the Guidelines International Network database (2011). 
With such a variety of CPG development groups, it is not surprising that conflicting or 
outright contradictory guidelines can exist simultaneously, leaving physicians wondering which 
recommendation(s) to adhere to.  Until very recently, prostate cancer screening was one of 
these topics with openly contradictory guidelines.   As Schmidt commented, “…when the U.S. 
Preventive Services Task Force (USPSTF) issued guidelines against prostate specific antigen 
(PSA) screening last May [2012], the American Urological Association responded with a 
scathing rebuttal: The move was outrageous, claimed the association, whose own guidelines 
take a far more favorable view of the PSA screen.  Covered widely in the media, the volatile 
debate over PSA tests pitted one set of clinical practice guidelines against another.” (Schmidt, 
2013: 2) 
Similarly, in a system lacking a central guideline-producing body or universal guideline 
review process, not all guidelines are equally valid or reliable.  In recent years, “stakeholders 
have questioned the quality and reliability of such guidelines. Concerns have focused…on the 
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quality of the evidence base of many guidelines, a lack of transparency in the creation of 
guidelines, and the handling of conflicts of interest to prevent bias” (Kuehn, 2011: 1847).   In 
response to these and many other concerns about guideline development, the Institute of 
Medicine (IOM) published a report entitled Clinical Practice Guidelines We Can Trust in March 
2011.  In the report, the IOM established eight standards for developing and maintaining CPGs, 
tackling issues of transparency, conflicts of interest, development group composition, 
establishing evidence bases, careful articulation of guidelines, external review and regular 
updating of CPGs (Institute of Medicine, 2011).   
 
Methods 
 
First, in order to gain a better understanding of the role prostate cancer screening 
guidelines play in the physician-patient relationship, I conducted a literature review focusing on 
prostate cancer screening decision-making from both physician and patient perspectives; the 
methods, findings and discussion of which are attached below (Appendix A). 
I then generated original data for this paper through critical inspection of five major 
clinical practice guidelines; these include the most recent versions (as of June 2013) of the 
American College of Physicians (ACP), American College of Preventive Medicine (ACPM), 
American Cancer Society (ACS), American Urological Association (AUA) and U.S. Preventive 
Services Task Force (USPSTF) guideline statements regarding prostate cancer screening.  I 
coded original data from these guideline statements.  In the specific case of the USPSTF clinical 
practice guideline, I considered the recommendation statement and the evidence summary 
publications in conjunction, treating them as the Task Force’s guideline for prostate cancer 
screening. 
I assessed each guideline for several variables, which were defined in advance to 
identify important characteristics of publishing bodies, CPG development committees, evidence 
review processes, clinical recommendations, and conflicts of interest (Table 1).  Publishing 
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body variables included the title of the guideline, publication date, the name and type of 
publishing organization, and to whom the guideline is targeted.  CPG development committee 
variables included committee group composition, and specific stakeholder (specialist, primary 
care and public) involvement in guideline creation.  Variables pertaining to the evidence review 
process included details of how the systematic review was conducted, the inclusion of Prostate, 
Lung, Colorectal and Ovarian (PLCO) and European Randomized Study of screening for 
Prostate Cancer (ERSPC) trial data in the review process, studies cited and their relative 
strengths according to the recommendation statement, and the external review process.  
Guideline variables included the age distinctions mentioned by the guideline and the actual 
guideline recommendation.  Finally, variables related to conflicts of interest included whether 
COIs were disclosed, and the procedure for addressing COIs beyond mere disclosure.  I chose 
these variables specifically to reflect many of the IOM criteria and to highlight important 
differences in the guideline development process and final recommendations of these 
organizations. 
 
Findings 
 
Publishing body characteristics (Table 2) 
 
First, I established some baseline characteristics of the publishing bodies of these 
guidelines.  Guidelines were published in 2008, 2010, 2012, and 2013 (two).  There were 
several types of organizations represented; three of these bodies were specialty societies, one 
was a disease society, and one was a government funded, independent panel.  Four of the 
clinical practice guidelines were written for primary care providers, while only one was intended 
for specialists – in this case, urologists. 
 
Clinical practice guideline development committee (Table 3) 
 
 5 
A common difficulty in producing trustworthy, unbiased guidelines is a lack of 
multidisciplinary involvement in the guideline development group.  Unfortunately, most 
guideline-producing committees are made up of members of a single-specialty society, who are 
predisposed to recommend guidelines that promote the interests of their own specialty 
(Shaneyfelt, 2012).  Shaneyfelt further remarks that this homogenous group composition leaves 
less room at the table for other important stakeholders, claiming that 
Expertise is needed in both clinical and nonclinical disciplines (eg, methodological 
experts, decision scientists, health economists)… expertise should include both 
generalists and subspecialists because each possesses different vantage points for the 
same clinical problem... generalist input is needed to temper the recommendations for 
patients with multiple morbidities…[and] patients or patient representative should be 
included…because they offer perspectives that clinicians and scientists can’t (2012: 
1633-1634). 
 
Having more diverse guideline development groups tends to mitigate individual biases, leading 
to more evidence-based guidelines (Shekelle, Woolf, Eccles & Grimshaw, 1999). 
All five of the guideline-issuing organizations named their committee members in their 
recommendations, which had no members in common with any other guideline evaluated in this 
paper.  Three of the five guidelines did not specify whether their guideline development 
committee had multidisciplinary membership; only the ACS and AUA recommendation 
statements indicated the involvement of primary care physicians as well as specialists.  Finally, 
only one guideline statement allowed for public commenting on the recommendation draft; no 
others reported involving the public in the CPG development process. 
 
Evidence review process (Table 4) 
 
Four of the guideline-developing bodies conducted their own systematic review of the 
literature; the remaining organization, the American College of Physicians, relied solely on 
review of other clinical practice guidelines available at the time when producing their own 
recommendation statement.  Of the four conducting their own reviews of the evidence base, one 
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(ACPM) gave no details of its review process, stating that the study “…reviewed the efficacy of 
DRE and PSA for prostate cancer screening found in the medical literature prior to July 2007.” 
Three guideline groups included the large, randomized PLCO and ERSPC trials; one 
group indirectly considered these trials (by way of reviewing other guidelines that had included 
the results of these studies in their deliberation), and one group did not include these RCTs in 
its evidence review, since only preliminary data from them were available at the time of its 
guideline development. 
Of the three groups including PLCO/ERSPC trials, which had seemingly conflicting 
results (with PLCO showing no statistically significant difference in prostate cancer mortality 
between screening and control groups, and ERSPC showing a slight reduction in prostate 
cancer mortality in the screening group), one weighted PLCO more heavily, one weighted 
ERSPC more heavily, and the remaining group weighted the two studies equally. 
 Finally, only three of the five CPG development groups evaluated in this paper included 
details of an external review process; two of these three circulated guidelines to peer reviewers, 
whereas the remaining group allowed public commenting on the recommendation draft before 
final publication of the guideline. 
 
Recommendation statements (Table 5) 
 Recommendation statements were quite diverse, with no two guidelines using the same 
age brackets in their recommendations, although three of the guidelines did recommend that 
men under 50 receive information regarding screening in order to facilitate informed decision-
making.  Overall, one guideline recommended strongly against PSA-based screening for 
prostate cancer (USPSTF), one claimed that there was insufficient evidence to make a 
recommendation (ACPM), and the remaining three advocated shared decision-making based on 
patient preferences and values, albeit with different age brackets used in their 
recommendations.  All five guidelines, regardless of recommendation, advocated either 
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informed or shared decision-making, and none advocated population-based screening without 
patients being informed about the benefits and harms of prostate cancer screening. 
  
Conflicts of Interest (Table 6) 
 
 
One of the largest sources of mistrust in CPGs is conflict of interest (COI), which can be 
either financial or intellectual in nature.  Financial COIs seem to be easier to grasp; they include 
any relationship, direct or indirect, in which a member of a CPG development group stands to 
gain financially from the guideline being developed.  Intellectual COIs, on the other hand, are a 
little more challenging to define, but can bias guidelines just as much as do their financial 
counterparts.  According to the ACP, examples of nonfinancial COIs include 
…leadership or close involvement in an advocacy group that stands to gain from a 
Clinical Guidelines Committee member’s opinion; being a chair or member of another 
guideline committee relevant to the topic under discussion; acting as an expert witness 
or having a membership…or relationship…with organizations and funding bodies…or a 
membership in a lobbying or advocacy organization; writing or consulting for an 
educational company; having personal relationships…with persons involved in the 
submission or evaluation of a paper…; and having personal convictions…related to a 
paper’s topic that may interfere with an unbiased publication process… (Qaseem, Snow, 
Owens & Shekelle, 2010: 195). 
 
 All five guidelines investigated in this paper disclosed financial conflicts of interest 
reported during the development process; one of these guidelines (ACPM) reported having no 
financial COIs, whereas the other four provided, in varying levels of detail, individuals and their 
reported financial relationships which may have influenced the guideline development process.  
Three guidelines provided no procedural detail for how they deal with COIs, other than the one-
time disclosure reported in their publication.  Two guidelines (USPSTF & ACP) posted their 
disclosures online, and only one guideline (AUA) distinguished between reported relationships 
that were compensated and those that were uncompensated. 
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Discussion  
 
 Many interesting themes emerged out of my critical evaluation of these five “major” 
prostate cancer screening guidelines.  In general, it was interesting to note that despite similar 
evidence bases, there were a variety of guideline statements, ranging from recommendations 
against PSA screening in all age groups (USPSTF) to insufficient evidence to make a 
recommendation (ACPM) to identifying specific age ranges where prostate cancer screening 
might be appropriate (AUA).  These findings are likely simultaneously based on and biased by 
the individual guidelines’ target audience; for example, the AUA’s reluctance to categorically 
recommend against screening may be in part due to the specialty’s case mix, which tends to be 
weighted toward patients with more aggressive prostatic cancer.   
Differences in recommendations despite similar evidence also shed light on the 
important role of expert opinion, value judgments and other “non-evidence” that is taken into 
account when crafting a guideline statement.  Only rarely in clinical practice guideline 
development is the evidence so abundant and clear that no other input is needed; much more 
often, evidence gaps are traversed using the clinical judgment of experts, committee members 
and other reviewers.  However, it is important that the role that these judgments play in the 
guideline development process be clearly delineated in order to provide transparency to 
consumers of these guidelines (clinicians).  This transparency was unfortunately lacking in most 
of the recommendation statements evaluated in this paper. 
 While the evidence basis for most of the guidelines focused on large RCTs conducted in 
both the U.S. and Europe, the ACPM guideline was formulated before results of these two major 
trials (PLCO and ERSPC) were readily available.  These two trials were the reason that many of 
the societies, most notably the USPSTF, changed their previous guideline statements to reflect 
a growing lack of evidence that prostate cancer screening’s benefits outweighed its harms.  The 
fluidity of the evidence base for prostate cancer screening (and more broadly, medicine in 
general) ensures that recommendations can and often will change over time. Thus, CPG 
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development groups should recognize the importance of timely updating of both systematic 
reviews of the literature as well as guideline statements, keeping in mind that clinical practice 
change can often lag behind the medical literature. 
A major area in which bias can be minimized is CPG development group selection.  
Selection processes should strive to include generalists, subspecialists, economists, 
epidemiologists, industry leaders, patients and other topic-specific stakeholders. Unfortunately, 
the majority of the publishing bodies studied in this paper either did not conduct such a process, 
or failed to report doing so.  Ensuring this sort of multidisciplinary approach allows the 
committee to hear all sides of complex, controversial issues, and to ensure that all parties feel 
invested in the final recommendation, a crucial component to guideline uptake by the larger 
medical community. Inclusion of diverse, issue-specific interest groups is often more compatible 
with an ad hoc structure of guideline development group, but similar principles can and should 
be applied to committees of all structures. 
Minimizing the potential bias that COIs pose is a much more difficult issue to tackle.  
Many groups have touted transparency as the answer to dealing with financial COIs, but despite 
a growing trend in disclosure over the past decade, most guideline committees contain panel 
members with significant COIs of both financial and intellectual natures (Neuman, Korenstein, 
Ross & Keyhani, 2011).  According to a recent study, less than 50% of the guidelines randomly 
screened provided any information on COIs; of those guidelines which provided this information, 
71.4% of chairpersons and 90.5% of co-chairpersons had COIs (Kung, Miller and Mackowiak, 
2012). 
Simply disclosing COIs on important CPG development groups may not be sufficient to 
prevent biased recommendations. Tougher approaches have been suggested to minimize this 
possibility; in order of increasing severity, they include requiring panel members to halt any 
current COIs, limiting the participation of those with COIs in panel discussions, allowing for 
recusal procedures for members with severe COIs as judged by their peers, and even banning 
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the selection of any members with COIs.  While all these approaches have merit (and many are 
being implemented by select groups), it is naïve to think that we will completely eradicate COIs 
from guideline development. Instead, we should attempt to change the culture surrounding 
guidelines, making it clear that guidelines (and their authors) are subject to the same scrutiny 
applied to other medical and basic science research. 
 
Conclusion 
 
After delving into the most recently published, “major” prostate cancer screening 
guidelines and the controversy surrounding the issue, it is clear that each and every one of 
these recommendation-issuing bodies falls short of the IOM standards for developing 
trustworthy guidelines.  Unfortunately, these findings seem to be indicative of the majority of 
clinical practice guidelines.  A 2011 study by Kung, Miller and Mackowiak screened 130 
randomly selected guidelines from the National Guideline Clearinghouse for adherence to 18 of 
the 25 IOM standards; only 49.1% of these CPGs met >50% of the standards assessed, with 
subspecialty-developed guidelines performing the poorest (only 39.0% met >50% of standards). 
 So why do these bodies fare so poorly when compared to IOM criteria?  One partial 
explanation is chronological in nature: the IOM released their criteria for developing trustworthy 
clinical practice guidelines in 2011, so it is conceivable that medical society guidelines were 
either developed before the IOM standards were released, or that guideline development 
groups were unaware that these standards existed.  However, a second explanation is more 
likely for guidelines published after the IOM’s report:  IOM standards for CPG development have 
not gained sufficient traction among the medical and scientific communities.  Tensions between 
specialists and primary care providers, and population- and individual-based approaches, as 
well as both financial and intellectual special interests constantly threaten to bias 
recommendation statements.  These conflicts are not only difficult to admit, but can be even 
more difficult to address, since the appropriate minimization of these potential sources for bias 
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is a field full of more questions than answers.  The fact remains, however, that just as health 
care providers have lagged behind CPG development group recommendations in the quantity 
and quality of informed/shared decision-making interactions with patients before prostate cancer 
screening (Appendix A), development groups themselves have been hesitant to adopt the 
rigorous standards prescribed by the IOM for trustworthy guideline development.   
The decision to undergo prostate cancer screening, like most medical decisions, should 
draw upon CPGs, clinical judgment and patient values; guidelines should be used as a 
component of, rather than in place of, the shared decision-making of patient-physician dyads.  
At their best, CPGs “…are supposedly evidence based, but the published evidence…is rarely 
sufficient to fill the evidence gap…a guideline [can] easily become a substitute for the evidence 
it is supposed to represent” (Gale, 2011: 1).   As prostate cancer screening demonstrates, well-
intentioned CPG-publishing bodies drawing on similar evidence can come to very different 
conclusions regarding the state of the literature.  Because they are so heavily relied upon for 
clinical decision-making, it is imperative that CPG-issuing groups strive to be transparent in all 
aspects of the guideline-crafting process, from beginning to end.  Despite these efforts, it 
remains of utmost importance that physicians critically evaluate these multiple 
recommendations, ever mindful that not all guidelines are created equal. 
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Table 1: Description of Variables 
Variable Name Input Type Variable Description 
   
pubguidetitle Text Title of publication(s) 
pubdate Date Date published 
pubbody Text Name of publishing body 
pubbodytype Text Publishing body type 
pubintendaud Text Intended audience (who the guideline is intended for) 
   
commcomp text Self-described committee composition 
commmulti yes/no Is the committee multidisciplinary? 
commspecialist yes/no Presence/Absence of specialists on the committee 
commpcp yes/no Presence/Absence of PCPs on the committee 
commpublic yes/no Presence/Absence of public involvement in guideline development 
   
srprocess text Self-described systematic review process 
srplcoerspc yes/no Included PLCO & ERSPC trials in review? 
srstudies text Studies cited 
srstrength text Strength of studies cited 
srextreview text External review process (if applicable) 
   
guideagebrackets age ranges Age distinctions for guidelines 
guiderec text Guideline recommendation 
   
coidisclose yes/no Are COIs disclosed? 
coiprocedure text How were COIs addressed 
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Table 2: Publication Characteristics 
pubguidetitle pubdate pubbody pubbodytype pubintendaud
ACP
Screening for 
Prostate Cancer: A 
Guidance Statement 
From the Clinical 
Guidelines Committee 
of the American 
College of Physicians
May 2013 American College of Physicians specialty society internal medicine physicians
ACPM
Screening for 
Prostate Cancer in 
U.S. Men: ACPM 
Position Statement on 
Preventive Practice
Feb 2008 American College of Preventive Medicine specialty society primary care physicians
ACS
American Cancer 
Society Guideline for 
the Early Detection of 
Prostate Cancer: 
Update 2010
March 2010 American Cancer Society disease society primary care physicians
AUA
Early Detection of 
Prostate Cancer: AUA 
Guideline
May 2013 American Urological Association specialty society urologists
USPSTF
Screening for 
Prostate Cancer: U.S. 
Preventive Services 
Task Force 
Recommendation 
Statement AND 
Screening for 
Prostate Cancer: A 
Review of the 
Evidence for the U.S. 
Preventive Services 
Task Force
May 2012 U.S. Preventive Services Task Force
independent 
panel (govt 
funded)
primary care physicians
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Table 3: CPG Development Committee Characteristics 
 
commcomp commmulti commspecialist commpcp commpublic
ACP
"Individuals who served on the Clinical Guidelines Committee from initiation of the project until its 
approval were: Paul Shekelle, MD, PhD (Chair); Roger Chou, MD; Molly Cooke, MD; Paul Dallas, MD; 
Thomas D. Denberg, MD, PhD; Nick Fitterman, MD; Mary Ann Forciea, MD; Robert H. Hopkins Jr., MD; 
Linda L. Humphrey, MD, MPH; Tanveer P. Mir, MD; Douglas K. Owens, MD, MS; Holger J. 
unknown unknown unknown unknown
ACPM
"The members of ACPM’s Prevention Practice Committee are: Gershon H. Bergeisen, MD, MPH; 
Michael T. Compton, MD, MPH; V. James Guillory, DO, MPH, FACPM (Chair); Doug I. Hammer, MD, 
MPH, DrPH; Joylene John-Sowah, MD, MPH; Steven Jonas, MD, MPH (Consultant); Elizabeth Kann, MD, 
MPH; Ronit B. Katz, MD, FACPM; Robin McFee, DO, MPH, FACPM; Elaine S. Perry, MD, MS; Jennifer E. 
unknown unknown unknown unknown
ACS
"American Cancer Society Prostate Cancer Advisory Committee: Andrew M. D. Wolf, MD 
(Chair)…Claudia R. Baquet, MD, MPH…Gerald Chodak, MD... Jennie Cook, American Cancer Society 
National Assembly Life Member, Larkspur, CA; Anthony V. D’Amico, MD, PhD…Ruth B. Etzioni, 
PhD…Thomas D. Fogel, MD…Paul A. Godley, MD, PhD, MPP…Cynthia M. LeBlanc, EdD, MA…Terry 
Mason, MD…Viraj Master, MD, PhD…Andrew L. Salner, MD…Virgil H. Simons…Ian M.Thompson, Jr., 
MD… and Richard C. Wender, MD… In addition, Robert J. Volk, PhD…Louise Walter, MD…and 
yes yes yes unknown
AUA
“The Panel was created by the American Urological Association Education and Research, Inc. (AUA). 
The Practice Guidelines Committee (PGC) of the AUA selected the Panel Chair and Vice Chair who in 
turn appointed a multidisciplinary panel with expertise in the guideline subject. All panel members 
were subject to and remain subject to the AUA conflict of interest disclosure criteria for guideline panel 
members and chairs. Panel members were predominantly urologists, and the target users of the 
guideline are urologists...Early Detection of Prostate Cancer Panel and Consultants: H. Ballentine 
Carter, MD; Peter C. Albertsen, MD; Ruth Etzioni, PhD; Stephen J. Freedland, MD; Kirsten Lynn Greene, 
yes yes yes unknown
USPSTF
“Members of the U.S. Preventive Services Task Force at the time this recommendation was finalized 
are Virginia A. Moyer, MD, MPH, Chair… Michael L. LeFevre, MD, MSPH, Co-Vice Chair…Albert L. Siu, 
MD, MSPH, Co-Vice Chair… Linda Ciofu Baumann, PhD, RN…Kirsten Bibbins-Domingo, PhD, MD…Susan 
J. Curry, PhD…Mark Ebell, MD, MS…Glenn Flores, MD…Adelita Gonzales Cantu, RN, PhD… David C. 
Grossman, MD, MPH…Jessica Herzstein, MD, MPH…Joy Melnikow, MD, MPH…Wanda K. Nicholson, 
MD, MPH, MBA…Douglas K. Owens, MD, MS…Carolina Reyes, MD, MPH… and Timothy J. Wilt, MD, 
unknown unknown unknown
yes (allowed 
for public 
comment on 
draft)
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Table 4: Evidence Review Process Characteristics 
srprocess srplcoerspc srstudies srstrength srextreview
ACP
“The ACP Clinical Guidelines Committee developed this guidance statement for clinicians by
assessing current guidelines developed by other organizations on screening for prostate cancer…by 
searching the National Guideline Clearinghouse for guidelines (August 2012)… [and] selected 4 
prostate cancer screening guidelines developed in the United States: …ACPM…ACS…AUA,,,and USPSTF. 
These guidelines were reviewed independently by 4 coauthors. We followed the AGREE II (Appraisal of 
Guidelines, Research and Evaluation in Europe) collaboration method…[which] asks 23 questions in 6 
domains: scope and purpose, stakeholder involvement, rigor of development, clarity and presentation, 
yes 
(indirectly)
ACS, ACPM, USPSTF and AUA 
guidelines
USPSTF>ACS>AUA=ACPM unknown
ACPM
“This study reviewed the efficacy of DRE and PSA for prostate cancer screening found in the medical 
literature prior to July 2007.” (164); No other details given about systematic review process
no 
(preliminary 
data only)
Epidemiologic studies evaluating 
DRE, Quebec and Norkoping RCTs, 
other recommendations (USPSTF, 
ACP, Canadian Task Force on 
Preventive Health Care, ACS, AAFP, 
AUA, Institute for Clinical Systems 
Improvement), preliminary 
ERSPC/PLCO data
Did not compare ERSPC/PLCO since only preliminary results of 
ERSPC available; acknowledged significant limitations of Quebec 
and Norkoping RCTs; did not directly compare strengths of other 
CPGs
unknown
ACS
“…search strategies addressed the following subdomains: 1) efficacy of screening in reducing 
mortality… 2) test characteristics of prostate cancer screening in asymptomatic men…and 3) physical 
and psychological harms associated with screening. Studies were identified by searching Medline for 
articles…published between January 1950 and June 2009…Two authors…independently reviewed 
titles, abstracts, and full texts for eligibility and independently abstracted data…any 
discrepancies…were resolved through discussion by the two authors. The results of the systematic 
reviews were provided to all members of the ACS Prostate Cancer Advisory Committee for review 
before meeting and were supplemented with presentations by experts…deliberations about the 
evidence occurred at the committee meetings and in a series of conference calls that preceded and 
followed the meeting.” (73)
yes
Quebec, Norrkoping, PLCO, ERSPC, 
various case-control 
studies/surveillance data/ecological 
studies
Significant methodologic limitations for case-control studies, 
Quebec and Norrkoping trials; acknowledged flaws in both ERSPC 
and PLCO trials, but did not give more weight to either RCT
“…the guideline with the 
supporting document was 
circulated to peer reviewers for 
feedback and then to the ACS 
Mission Outcomes Committee for 
review. The Mission Outcomes 
Committee approved the 
guideline, suggested modifications 
to the supporting document, and 
forwarded the documents to the 
ACS Board of Directors for final 
approval.” (73-74)
AUA
“The AUA commissioned an independent group to conduct a systematic review…the protocol…was 
developed a priori by the expert panel. The search strategy…spanned across multiple 
databases…controlled vocabulary supplemented with keywords was used to search for the relevant 
concepts of prostate cancer, screening and detection…The outcomes of interest were also a priori 
determined by the Panel and included prostate cancer incidence, mortality, quality of life, the 
diagnostic performance of each of the tests and the harms of testing… Modeling studies were included 
when original studies were limited by follow-up time and screening protocols. The methodology team 
independently rated the methodological quality of the studies and provided an overall judgment of the 
whole body of evidence based on their confidence in the available estimates of effect. The framework 
for rating the quality of evidence is an adaptation and modification of the GRADE framework…In this 
adaptation, the AUA rates the quality of evidence as high, moderate or low (A, B or C)…based on study 
yes
Stockholm, Norrkoping, Quebec, 
ERSPC, Goteborg, PLCO, population 
data, modeling studies
Significant methodologic flaws with Stockholm, Norrkoping and 
Quebec studies: "Stockholm trial screened with only one test and a 
high cut-off of PSA for biopsy; the Stockholm, Norrkoping and 
Quebec trials lacked allocation concealment; and the Quebec trial 
did not report according to intention to screen." (6) Relied heavily 
on modeling studies; gave more weight to ERSPC than PLCO due to 
significant contamination in PLCO
“The initial draft of this Guideline 
was distributed to 52 peer 
reviewers; 25 responded with 
comments. The Panel reviewed 
and discussed all submitted 
comments and revised the draft 
as needed. Once finalized, the 
Guideline was submitted for 
approval to the PGC. It was then 
submitted to the AUA Board of 
Directors for final approval.” (5)
USPSTF
“…detailed methods and data for the review, including search strategies, multiple evidence tables with 
quality ratings of individual studies, and pooled analyses of some harms data, are available in the full 
report… searched Ovid MEDLINE from 2002 to July 2011, PubMed from 2007 to July 2011, and the 
Cochrane Library Database through the second quarter of 2011 and reviewed reference lists to identify 
relevant articles published in English.  At least 2 reviewers independently evaluated each study to 
determine inclusion eligibility...one investigator abstracted details on the patient population, study 
design, analysis, duration of follow-up, and results. A second investigator reviewed data abstraction for 
accuracy. Two investigators independently applied criteria developed by the USPSTF to rate the quality 
of each study as good, fair, or poor. Discrepancies were resolved through a consensus process. We 
assessed the aggregate internal validity (quality) of the body of evidence...on the basis of the number, 
quality, and size of studies; consistency of results between studies; and directness of evidence.” (763)
yes
PLCO, ERSPC, Goteborg, Quebec, 
two other RCTs, 
Quebec and two other RCTs deemed “poor quality” due to 
“…failure to describe adequate randomization or allocation 
concealment methods, poorly described loss to follow-up, and 
unclear masking of outcomes assessors…one trial used a high PSA 
cut point” (764);  "Both the ERSPC and PLCO trials were heavily 
weighted by the USPSTF in its considerations, because they had 
the largest populations and were of the highest quality, although 
both had important—but different—methodological limitations. 
The screening intervals, PSA thresholds, use of digital rectal 
examinations, enrollee characteristics, and follow-up diagnostic 
and treatment strategies used in the PLCO trial are most applicable 
to current U.S. settings and practice patterns." (127)
"A draft version of this 
recommendation statement was 
posted for public comment on the 
USPSTF Web site from 11 October 
to 13 December 2011." (127)
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Table 5: Guideline Characteristics 
 
guideagebrackets guiderec
ACP
under 50; 50-69; 
over 69
“…that clinicians inform men between the age of 50 and 69 years about the limited potential benefits 
and substantial harms of screening…base the decision to screen for prostate cancer using the prostate-
specific antigen test on the risk for prostate cancer, a discussion of the benefits and harms of 
screening, the patient’s general health and life expectancy, and patient preferences….clinicians should 
not screen for prostate cancer using the prostate-specific antigen test in patients who do not express a 
clear preference for screening[,]…in average-risk men under the age of 50 years, men over the age of 
69 years, or men with a life expectancy of less than 10 to 15 years.” (7)
ACPM
no explicit age 
brackets; 
acknowledges the 
"usual" age for 
screening is 50-70 
“The American College of Preventive Medicine concludes that there is insufficient evidence to 
recommend routine population screening with DRE or PSA. Clinicians caring for men, especially African-
American men and those with positive family histories, should provide information about potential 
benefits and risks of prostate cancer screening, and the limitations of current evidence for screening, in 
order to maximize informed decision making.” (164)
ACS Under 50; Over 50
“The ACS recommends that asymptomatic men who have at least a 10-year life expectancy have an 
opportunity to make an informed decision with their health care provider about screening for prostate 
cancer after they receive information about the uncertainties, risks, and potential benefits associated 
with prostate cancer screening. Prostate cancer screening should not occur without an informed 
decision-making process. Men at average risk should receive this information beginning at age 50 
years. Men in higher risk groups should receive this information before age 50 years. Men should 
either receive this information directly from their health care providers or be referred to reliable and 
culturally appropriate sources. Patient decision aids are helpful in preparing men to make a decision 
whether to be tested.” (74)
AUA
Under 40; 40-54; 
55-69; Over 69
“1. The Panel recommends against PSA screening in men under age 40 years. (Recommendation; 
Evidence Strength Grade C) 
2. The Panel does not recommend routine screening in men between ages 40 to 54 years at average 
risk. (Recommendation; Evidence Strength Grade C); For men younger than age 55 years at higher risk 
(e.g. positive family history or African American race), decisions regarding prostate cancer screening 
should be individualized. 
3. For men ages 55 to 69 years the Panel…strongly recommends shared decision-making for 
men…considering PSA screening, and proceeding based on a man’s values and preferences. (Standard; 
Evidence Grade B)
4. To reduce the harms of screening, a routine screening interval of two years or more may be 
preferred over annual screening in those men who have participated in shared decision-making and 
decided on screening…(Option; Evidence Strength Grade C) 
5. The Panel does not recommend routine PSA screening in men age 70+ years or any man with less 
than a 10 to 15 year life expectancy. (Recommendation; Evidence Strength Grade C)” (1-2)
USPSTF None
“The USPSTF recommends against prostate-specific antigen (PSA)– based screening for prostate cancer 
(grade D recommendation)…although the USPSTF discourages the use of screening tests for which the 
benefits do not outweigh the harms in the target population, it recognizes the common use of PSA 
screening in practice today and understands that some men will continue to request screening and 
some physicians will continue to offer it. The decision to initiate or continue PSA screening should 
reflect an explicit understanding of the possible benefits and harms and respect the patients’ 
preferences. Physicians should not offer or order PSA screening unless they are prepared to engage in 
shared decision making that enables an informed choice by the patients. Similarly, patients requesting 
PSA screening should be provided with the opportunity to make informed choices to be screened that 
reflect their values about specific benefits and harms. Community- and employer-based screening 
should be discontinued.” (120, 123)  
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Table 6: Conflict of Interest Disclosure and Procedure 
 
 
coidisclose coiprocedure
ACP yes
“A record of conflicts of interest is kept for 
each Clinical Guidelines Committee meeting 
and conference call” (8); Financial COIs 
disclosed in statement and online; funding 
support reported; other than disclosure, 
procedure unknown
ACPM yes (none)
“No financial disclosures were reported by 
the authors of this paper.”(169); other than 
reporting, procedure unknown
ACS yes
Financial COIs and grant support disclosed; 
other than reporting, procedure unknown
AUA yes
“Funding of the committee was provided by 
the AUA. Committee members received no 
remuneration for their work. Each member 
of the committee provides an ongoing 
conflict of interest disclosure to the AUA.  
Relationships that have expired (more than 
one year old) since the panel’s initial 
meeting, are listed. Those marked with (C) 
indicate that compensation was received; 
relationships designated by (U) indicate no 
compensation was received.” (28)
USPSTF yes
“Disclosure forms from USPSTF members 
can be viewed at  
www.acponline.org/authors/icmje/Conflict
OfInterestForms.do?msNum=M12-1086.” 
(132)  
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APPENDIX A: Systematic Review 
 
Decision-Making in Prostate Cancer Screening: A Review of the Literature 
 
Introduction 
In May 2012, the U.S. Preventive Services Task Force (USPSTF) released its most 
recent guidelines for prostate cancer screening; in its statement, the Task Force recommended 
against population-based screening, giving prostate-specific antigen (PSA) testing a Grade D 
recommendation for men of all ages.  In issuing its guideline, the USPSTF cited a lack of 
evidence that the benefits of PSA-based prostate cancer screening outweighed the 
demonstrable harms of such testing.1  The USPSTF’s recommendation did not preclude the use 
of PSA testing altogether; however, the Task Force insisted that physicians “not offer or order 
PSA screening unless they are prepared to engage in shared decision making that enables an 
informed choice by patients” and that patients “be provided with the opportunity to make 
informed choices…that reflect their values about specific benefits and harms.”1  
Despite these recommendations, there is growing evidence that providers continue to 
offer prostate cancer screening without engaging in the type of shared decision-making the 
USPSTF deems essential to informed patient choice. Many patients report that their health care 
provider failed either to provide sufficient information regarding the harms of screening or to ask 
for patient input when deciding whether to undergo screening; even “well-informed” patients 
consistently demonstrate poor knowledge, and overestimate incidence of cancer, mortality, and 
predictive value of PSA testing.2   
The purpose of this paper will be, through a review of the literature, to delineate both 
patient and provider roles in making the decision to undergo prostate cancer screening.  This 
paper will also highlight strengths and limitations of current shared decision-making models as 
they relate to prostate cancer screening and propose a decision-making framework for patients 
and clinicians to apply to PSA-based prostate cancer screening. 
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Methods 
 I performed a review of the literature, searching MEDLINE and Web of Science 
databases for relevant articles in English from 4/20/2008 to 4/20/2013, the date of the search.  
MeSH terms were chosen through consultation with a research librarian, as well as from key 
sentinel articles found during preliminary searches. My search strategy included the use of both 
MeSH terms and selected keywords; my exact search string was: 
 
((physician-patient relations OR patient participation OR communication OR 
decision making) AND (prostatic neoplasms OR PSA OR prostate-specific 
antigen) AND (mass screening OR early detection of cancer))   
 
The search strategy detailed above yielded 164 MEDLINE and 42 Web of Science 
articles (206 articles total).  From these 206 publications, I methodically selected articles which 
were deemed relevant to the key objective, which was elucidating the roles patients and 
providers play in prostate cancer screening decision making.  During my first stage of review, I 
excluded articles on the basis of title alone; reasons articles were excluded during this stage 
were 1) lack of relevance to the research question 2) duplicate publications found in both 
databases 3) clinical screening guidelines or commentaries on guidelines 4) publications 
regarding specific decision aids.  After this stage, the 46 remaining publications were evaluated 
on the basis of their abstracts.  After examining the abstracts, I excluded another 30 
publications from consideration.  I excluded articles in this phase for: (1) lack of relevance to the 
research question; (2) being a letter, editorial, or commentary on another publication; (3) not 
conducted in the United States; and (4) focused on prostate cancer treatment instead of 
screening.  I read the remaining 16 articles carefully and in their entirety. I excluded a total of 
four publications in this final review stage; three of these articles I was unable to review due to 
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lack of access to the full-text publication, and one was excluded since it included the same 
results as another study included in this final stage (of which I picked the publication dedicated 
solely to prostate cancer screening, and excluded the article that dealt with a myriad of cancer 
screenings). 
 
Results  
 The twelve remaining publications included four cross-sectional surveys of patients, four 
cross-sectional surveys of providers, one cross-sectional survey of both patients and providers, 
and three qualitative studies.  Three publications addressed the decision making process of 
African American men, a high risk group who tends to have both a greater incidence and more 
aggressive forms of prostate cancer.  Finally, four of the publications surveyed either providers 
or patients on a national level, while eight sampled from specific geographic areas within the 
United States. 
 
Patient Surveys 
Upon reviewing the literature, I found four cross-sectional surveys regarding patients and 
the prostate cancer screening decision-making process; summaries of the aims, methods, 
findings and limitations of each study are detailed below. 
 
Allen et al.3 
 Allen et al. surveyed 812 men at 12 separate worksites in Massachusetts from 2006-
2007 regarding their involvement in the decision-making process, as well as their knowledge of 
prostate cancer screening, decisional consistency, decision self-efficacy and social influences 
on the decision-making process.  They found that only 46% of men reported having a 
discussion regarding prostate cancer screening, and that only about a third of men had made an 
explicit decision about screening despite the fact that nearly half had undergone screening.  
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Furthermore, physician discussion was correlated with increased prostate cancer screening 
knowledge as well as patient decisional self-efficacy.    
 
Hoffman et al.4 
Hoffman et al. aimed to characterize patient screening decision-making while also 
evaluating factors associated with the process.  They conducted a telephone survey from 
November 2006 to May 2007 of 375 men who had either undergone or discussed PSA testing in 
the past two years.  When they occurred, prescreening discussions were initiated by the 
provider 64.6% of the time.  30.1% of patients reported being tested without ever discussing 
screening before hand. 54.8% of patients were asked for their screening preference, and only 
20.6% of physician-patient discussions addressed both pros and cons of testing before eliciting 
testing preference.  However, 60.1% of patients still felt as though they had taken part in shared 
decision-making, and performance on knowledge questions was inversely related to the 
perception of being informed.  This study was especially susceptible to recall bias since it relied 
on patient self-report, often two or more years after discussing or undergoing PSA testing, and 
was limited in its generalizability since a large number of the study participants were affluent, 
married and of Caucasian descent. 
 
Ross et al.5 
Using data from the National Health Interview Survey in 2000, Ross et al. examined the 
prevalence of physician-patient discussions of the pros and cons of PSA screening among 322 
African American men over 40 years of age, who had received at least on PSA test in their 
lifetime. 73.8% of these men reported having discussed the benefits and harms of PSA testing 
with their physician, however, a majority of men incorrectly perceived themselves to be at low 
risk (69.4%).  This study was especially susceptible to recall bias, since the time since last PSA 
was quite long in some cases, and possibly because men’s most recent PSA may have been 
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performed without their knowledge.  In addition, this study did not address the length or quality 
of these prescreening discussions, only whether or not they occurred.  Finally, the study did not 
differentiate whether the providers serving this population were primary care physicians or 
specialists. 
 
Williams et al.6 
Williams et al. attempted to assess African American men’s desired level of engagement 
in shared decision-making regarding prostate cancer screening, as well socio-demographic 
characteristics associated with shared decision-making preferences.  The authors conducted 
telephone interviews of 286 African American members of the Prince Hall Masons (D.C. area), 
ages 40-70.  In these interviews, they assessed prostate cancer knowledge, decisional conflict 
(using DCS), satisfaction with their screening decision, and preferred level of shared decision-
making (using Degner SDM, where 1. the doctor alone should decide; 2. mostly the doctor 
should decide; 3. the doctor and you should decide equally; 4. mostly you should decide; 5. you 
alone should decide); they later collapsed this scale to either doctor (1 & 2), shared (3), or 
patient (4 & 5).  They found that 57% of patients preferred shared decision-making, 36% 
preferred making their own decision, and only 7% wanted the doctor to make the decision.  
Older men, college graduates, and more educated persons were more likely to prefer shared 
decision-making, whereas younger men were more likely to prefer to make the decision 
themselves.  The study, while attempting to measure decision-making engagement in the 
African American population, picked a quite homogenous population to study, since members of 
the Prince Hall Masons are mostly older middle to upper middle class African American men.  
The result of studying this particular population is that the study may not apply to the African 
American population as a whole. 
Additional Comments 
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A limitation of all four studies was that they relied on patient self-report to characterize 
the decision-making process, making all four studies susceptible to potential recall bias.  In 
addition, the studies conducted by Allen et al.3 and Williams et al.6 were confined to a well-
defined geographic region (Massachusetts and Washington D.C., respectively), and are thus 
limited in their generalizability to the nation. 
 
Provider Surveys 
I also retrieved four cross-sectional descriptive surveys of physician attitudes toward the 
shared decision-making process, and have briefly summarized each study’s aims, methods, 
findings and limitations below. 
 
Davis et al.7 
Davis et al. assessed primary care provider attitudes toward shared decision making 
using a cross-sectional descriptive survey of 135 interns, residents, academic and community 
clinicians in the Washington D.C. area from 2007-2008.  The vast majority of providers surveyed 
favored either shared decision-making or that patients made the decision to undergo screening. 
More than half of providers were in favor of annual PSA testing, despite only a little over a third 
of providers believing that the sensitivity and specificity of the test was adequate.  More than 
half of providers espoused barriers to shared decision making such as competing health 
demands, lack of time, and a low level of patient interest.  This study was limited by its relatively 
low sample size, and might not be generalizable beyond the D.C. area. 
 
Hall et al.8 
Hall et al. used data from the 2007-2008 National Survey of Primary Care Physician 
Practices Regarding Prostate Cancer Screening, in which they surveyed 1256 primary care 
providers in order to examine the relationship between primary care provider discussion and 
 25 
recommendation of screening and other practice and physician related factors.  80.1% of 
physicians in this study reported discussing screening with all of their patients; of these 
screeners, 64.1% encouraged PSA testing, 34.4% remained neutral, and only 1.5% 
discouraged testing.  The authors identified two major groups, which they termed “routine 
screeners” and “non-routine screeners”: routine screeners were more likely to recommend PSA 
testing and engage in less prescreening discussion with their patients regardless of the 
evidence, while non-routine screeners were more likely to be neutral or recommend against 
PSA testing, and encouraged prescreening discussions with their patients.  The likelihood of 
providers routinely discussing prostate cancer was greater if the PCP was African American or 
Asian, and was directly related to the provider’s weekly patient volume and time spent in patient 
care. 
 
Linder et al.9 
Linder et al. explored the use of pre-screening discussions by providers to promote 
informed decision-making.  In February 2004, the authors surveyed 63 PCPs from a university-
based family medicine clinic and six community health centers in Houston.  20.6% of physicians 
reported not using prescreening discussions; these providers who did not routinely discuss 
prostate cancer screening with their patients generally ordered PSA tests anyway, while those 
who did discuss the benefits and harms of testing either let patients decide or actively 
recommended testing. A limitation of this study was the fact that it took place in an academic 
setting, which affects the generalizability of the study to other rural or urban settings. 
 
Volk et al.10 
 Volk et al. explored the use of prescreening discussion of benefits and harms by 
physicians, as well as beliefs about efficacy and contextual factors related to whether they have 
these discussions.  From 2007-2008, the authors surveyed 246 members of the American 
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Academy of Family Physicians National Research Network, allowing physicians to self-report 
their screening and discussion practices.  The authors found 24.3% of family medicine 
physicians routinely screened patients for prostate cancer without discussion, 22.6% discussed 
the pros and cons of screening and ultimately recommended PSA testing, 44.7% discussed 
pros and cons and allowed the patient to decide, 3.7 % discussed pros and cons but ultimately 
recommended against PSA screening, and 1.2% who did not discuss or recommend screening.  
Physicians who screened without discussion were less likely to practice at an academically 
affiliated site.  Physicians who discussed pros and cons but ultimately allowed their patients to 
decide whether or not to undergo PSA testing were more likely to believe that patients had a 
right to know about the lack of evidence behind prostate cancer screening, whereas physicians 
who ordered PSA testing without discussion believed that patients wanted testing, and that 
discussion and education about the benefits and harms of screening was not required.  This 
study was limited to family practitioners, who may have a different distribution of practice styles 
than primary care physicians in general. 
 
Additional Comments  
 All four studies are limited by the data being self-reported by physicians, who may over- 
or underestimate the occurrence and/or quality of prescreening discussions; in order to 
accurately evaluate how often discussions about prostate cancer screening take place, authors 
would need to directly measure their frequency, which is understandably difficult and time-
consuming.  In addition, the studies by Davis et al.7 and Linder et al.9 have limited 
generalizability since they were conducted in specific geographic regions (Washington, D.C. 
and Houston, TX, respectively). 
 
 
Survey of Both Patients and Providers 
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 One cross-sectional, descriptive survey addressed both patient and provider factors 
influencing decision-making; it is summarized below. 
 
Bowen et al.11 
In 2004, Bowen et al. used a state-wide, population based survey of 1680 men and 345 
primary care providers in order to determine the extent of informed decision making involved in 
prostate cancer screening from both the patient and provider perspective.  43.3% of men 
reported having PSA in the past year without discussing screening, whereas 74% of physicians 
reported “always or almost always” discussing risks and benefits of PSA testing.  When these 
discussions did take place, 64% of providers reported discussing the test’s performance 
characteristics, but only 35% discussed more “downstream” issues, like side effects from 
prostate cancer treatment.  The study did have a few major limitations, namely a response rate 
of only 43%, and the fact that the providers surveyed were not the same providers that the 
patients were reporting on, and vice-versa.  Since this survey relied on both patient and provider 
self-report, it is subject to the same limitations as described above in the patient survey and 
provider survey sections; this survey was conducted in the state of Washington, which again 
may make the results of this survey not easily generalizable to the whole country. 
 
Qualitative studies 
Finally, three publications were qualitative in design.  Again, I have summarized the 
aims, methods, findings and limitations of each study below. 
 
Ferrante et al.12 
Ferrante et al. attempted to explore factors associated with patient’s prostate cancer 
decision making using qualitative, semi-structured interviews from 2009-2010 of 64 Northern 
New Jersey men who were either new to screening or had a previous abnormal screen.  The 
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few men in the study who reported some understanding of the benefits and risks of screening 
reported that this knowledge came from friends, family members or media sources and not 
through discussions with health care providers, and none of the men who had been screened 
reported being informed of the risks of PSA screening.  The authors noted two types of men 
who were never screened, who they described as “passive avoiders”, who would have 
undergone screening if their PCP recommended it, and “active refusers”, who chose to decline 
screening for various reasons, including the perception of low risk, skepticism about screening 
benefits, not wanting to know, and confusion over screening procedures.  This study was mainly 
limited in its generalizability, as it was mostly composed of white, educated men. 
 
Jones et al.13 
Jones et al. explored how rural African American men make the decision to undergo 
prostate cancer screening, using a qualitative study design of one-on-one interviews of 17 
African American men from central rural Virginia with no previous history of prostate cancer.  
One of the major themes that emerged from these interviews were limited education about 
prostate cancer; men in this study were unaware that African Americans in particular are at 
higher risk, and desired more information about prostate cancer.  Another theme was the 
importance of family involvement; many men reported that family members were their most 
trusted advisors while going through the decision making process.  The final theme that 
emerged was the necessity for trust in health care providers; those men whose providers 
recommended screening were much more likely to do it.  While the study showed that men 
wanted more information regarded screening, this study did not address whether this indicated 
a desire for a more active role in decision-making. In addition, most men in the study were 
employed, insured, and had previous PSA screening, which all limit the study’s generalizability.   
 
Leader et al.14 
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Leader et al. used a qualitative study of 146 patient-physician encounters at two general 
internal medicine practices and one family/community medicine practice in Philadelphia in order 
to measure the extent of informed decision making about prostate cancer screening.  Audio 
recordings of these encounters were dual coded using IDM-9, which scored the content of 
prescreening discussions using nine elements of informed decision-making.  The mean total 
IDM-9 score was 2.7, meaning that, on average, less than 3 elements related to informed 
decision making were discussed per encounter, and 15% of encounters had no discussion or 
informed decision-making.  The most commonly discussed informed decision making elements 
were the nature and context of the decision (74% and 56%, respectively), and the least 
discussed were the patient’s role (6%) and desire for input from trusted others (3%).  The major 
limitation of this study was the fact that this IDM-9 measure had not been validated before this 
study, and was only able to measure the relative level of informed decision making taking place 
in these discussions. 
 
Discussion 
 In comparing the findings of these 12 publications, I found many themes regarding 
providers, patients and the prostate cancer screening decision-making process.  On the 
provider side, multiple studies alluded to a natural tension between clinical practice guidelines at 
the time, which often stated that the evidence for prostate cancer screening was insufficient or 
incomplete, and the concern over repercussions of missing a cancer diagnosis.  This tension 
manifested itself in a “pressure” felt by PCPs to screen patients for prostate cancer even though 
many clinicians had serious doubts about the evidence for doing so and the adequacy of the 
test.   In addition, providers may have been hesitant to initiate conversations about PSA 
screening due to the constant state of flux of the evidence as well as the significant controversy 
surrounding it, and may have been only discussing the benefits and harms associated with 
screening when patients brought it up during a routine visit.  Throughout a few of the studies, 
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different styles of practice also emerged; especially interesting were the trends of “routine 
screeners” and “non-routine screeners”, where routine screeners were pro-PSA but tended to 
not engage their patients in discussion, and non-routine screeners were either neutral or against 
PSA testing and were more likely to discuss the benefits and risks of screening.8  This is a 
disturbing trend: non-routine screeners seem to be practicing more in line with the clinical 
guidelines, which stress the importance of informed/shared decision-making, but routine 
screeners seemed to continue their practicing styles even in the face of shifting clinical practice 
guidelines and evidence.  This has implications for the effect of the most recent guidelines from 
the USPSTF on screening policy.  The USPSTF recommends against population based 
screening for prostate cancer using PSA, a recommendation routine screeners will likely be 
slow to adopt.1  Finally, these studies suggest that a group of physicians who do not discuss the 
harms and benefits of PSA screening continue to recommend testing because they feel that 
patients want testing and that educating patients is not worth it, from a practical standpoint.10  By 
taking this approach, where the focus is on the decision and not the decision-making process, 
physicians do a great disservice to their patients.   According to the principle of patient 
autonomy, patients have the right to know the benefits and harms of the diagnosis and 
treatment choices that are laid out before them even if such evidence would not lead to a 
change in decision.  Until physicians treat prostate cancer screening as a serious medical 
decision akin to prostate cancer treatment, which emphasizes communication of benefits and 
harms, careful deliberation, and subsequent patient or shared decision-making based on patient 
values, prostate cancer screening will continue to be ordered as an add-on test, with many 
patients unaware of what they are getting themselves into or that they had a choice in the 
matter. 
 From a patient perspective, there are also some interesting themes emerging from my 
review of the prostate cancer screening decision-making literature.  Patients often feel part of 
the decision-making process despite not being well-informed4, a problem that we can partially 
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blame on poor communication on the part of the provider.  However, it is also important that 
patients are activated consumers of health care, who understand the critical role they play in the 
decision-making process.  Despite the popularity of using decision aids for difficult choices in 
the doctor’s office, using aids at that point may in fact be too late.  If we want to promote more 
truly informed/shared decision-making, attempts should be made to tackle the problem 
“upstream”, by activate patients in the community through education, awareness and other 
media campaigns about how to be their own patient advocate.  These campaigns should 
educate patients about the choice behind prostate cancer screening, including the benefits and 
harms of screening, screening modalities, and test performance characteristics.   
 African American men, according to these studies, may require their own targeted 
approach.  This group is at high risk of developing aggressive prostate cancer, and is often not 
aware that they are considered high-risk. They not only bear a greater burden of disease, but 
also have distinct factors that affect screening that differ from the general population.  Trust in 
providers and the health care system is a major barrier to screening and decision-making in this 
population; according to Jones et al., these men are more likely to rely on family members and 
community leaders for information and advice13, so community interventions described above 
may need to be tailored to the way in which these men gather information and make decisions. 
 
Conclusion 
Patient reported rates of prescreening discussions ranged from 46.0% to 73.8%,3,5 
whereas the percentage of physicians who reported routinely using these discussions ranged 
from 71.0% to 80.1%.8,9,10,11  This suggests that physicians may believe that these discussions 
are occurring and that they are communicating these ideas, but patients may be unaware of it.  
It is clear that, even when prescreening discussions do occur, the quality of the discussions is 
low14, and that primary care providers continue to fall short in their task of promoting 
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informed/shared decision-making.  So, how can we improve the quality of these prescreening 
discussions? 
A necessary first step is defining what exactly we mean by “shared decision-making”.  In 
their systematic review of the shared decision-making literature, Makoul and Clayman split the 
elements of shared decision making in the literature into two different categories: essential and 
ideal.  The essential elements they proposed were defining/explaining the problem, presenting 
options, discussing the pros and cons, patient values/preferences, discussing patient ability or 
self-efficacy, doctor knowledge and recommendations, checking or clarifying understanding, 
explicitly making or deferring a decision and arranging appropriate follow-up.15 This list, while 
not necessarily exhaustive, is aptly named: if one of these issues is not addressed or brought to 
the table, the process is not truly “shared” between the patient and physician.  Early in their 
training, physicians should be exposed to these tenets of shared decision-making, and should 
structure their conversations with patients according to this checklist.  Doing so will not only 
improve the quality of physician-patient interactions including, but not limited to, prescreening 
discussions, but will likely lead to better outcomes as well, since patients will be much more 
informed about and invested in the medical decisions that they make. 
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